Mechanism of immune suppression induced by measles virus
麻疹病毒引起的免疫抑制机制
基本信息
- 批准号:10470083
- 负责人:
- 金额:$ 3.2万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B).
- 财政年份:1998
- 资助国家:日本
- 起止时间:1998 至 1999
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Human CD46, formerly membrane co factor protein (MCP), binds and inactivates complement C3b and serves as a receptor for measles virus (MV), thereby protecting cells from homologous complement and sustaining systemic measles infection. Suppression of cell-mediated immunity including down-regulation of IL-12 production has been reported on macrophages (Mφ) by crosslinking their CD46. The intracellular events responsible for these immune responses, however, remain unknown. Here, we found that 6-8 day GM-CSF-treated peripheral blood monocytes acquired the capacity to recruit SHP-1 to their CD46 and concomitantly were able to produce IL-12 p40 and nitric oxide (NO). Within the same time frame, Mφ acquired the capacity to assemble CD9, alphaS betal integrin to their CD46. Mφ earlier to this maturation stage were able to potentiate MV (Edmonston and Nagahata strain) replication, but in the activation stage NO and cytokines were induced and MV replication was severely suppressed. Direct ligation of CD46 by C3b, mAbs F(ab')_2 or MV H/F glycoproteins, but not intracellular MV replication, was required for these cellular responses. Interestingly, the KO strain failed to replicate in the 6-8 day GM-CSF-cultured Mφ while other MV strains replicated to form syncytia under the same conditions. When stimulated with the KO strain, rapid and transient dissociation of SHP-1 from CD46 was observed. Taken together, CD46 first serves as a receptor for MV, then recruits a molecular complex as depending upon maturation stages of human Mφ. These results provide strong evidence that CD46 serves as a signal-transducing molecule and that the properties of ligands determine suppression or activation of innate immune system. MV-mediated immune suppression may in part be attributable to the CD46 signaling.
人CD46(以前是膜的co蛋白(MCP))结合并失活的补体C3B并用作麻疹病毒(MV)的受体,从而保护细胞免受同源的完成和持续的全身麻疹感染。通过交联通过交联CD46,已经报道了细胞介导的免疫抑制的抑制,包括巨噬细胞(Mφ)的下调IL-12的下调。然而,负责这些免疫复杂的细胞内事件仍然未知。在这里,我们发现经GM-CSF处理的6-8天的外周血单核细胞获得了将SHP-1募集到其CD46的能力,并同时能够生产IL-12 p40和一氧化氮(NO)。在同一时间范围内,Mφ获得了组装CD9的能力,Alphas betal整合素与CD46的能力。早期到该成熟阶段的Mφ能够潜在地位(Edmonston和Nagahata菌株)复制,但是在激活阶段,NO和细胞因子被诱导并严重抑制了MV复制。这些细胞反应是由C3B,C3B,MABS F(AB')_ 2或MV H/F糖蛋白的直接连接,而不是细胞内MV复制。有趣的是,KO菌株在6-8天的GM-CSF培养Mφ中未能复制,而其他MV菌株在相同条件下复制以形成合成曲霉。当用KO应变刺激时,观察到SHP-1从CD46的快速和瞬时解离。综上所述,CD46首先用作MV的接收器,然后根据人Mφ的成熟阶段募集分子复合物。这些结果提供了有力的证据,表明CD46用作信号传递分子,并且配体的特性决定了先天免疫系统的抑制或激活。 MV介导的免疫抑制可能部分归因于CD46信号。
项目成果
期刊论文数量(104)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Kurita-Taniguchi, M., Seya T. et al.: "Activation of human macrophages through CD46 (measles virus receptor) : Production of IL-12 p40 and nitric oxide in association with recruitment of SHP-1 to CD46"J. Immunol.. 165. 5143-5152 (1998)
Kurita-Taniguchi, M., Seya T. 等人:“通过 CD46(麻疹病毒受体)激活人类巨噬细胞:IL-12 p40 和一氧化氮的产生与 SHP-1 募集到 CD46 相关”。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Seya,T.: "Human membrane cofactor protein of complement (CD46): multiple isoforms and functions." Int.J.Biochem.Cell Biol.(in press). (1999)
Seya,T.:“补体人膜辅因子蛋白 (CD46):多种亚型和功能。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Murakami, Y., T. Seya et. al.: "Effect of mutations at the residues R25 D27 P69 and N70 of B95a-MCP on receptor activities for the measles virus Nagahata wild-type strain and CAM vaccine strain"Int. J. Mol. Med.. 3. 25-32 (1999)
Murakami,Y.,T. Seya 等。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Seya,T.: "CD46 (membrane cofactor protein (MCP) of complement,measles virus receptor):structurland functional divergence among species(Review)." Int.J.Molec.Med.21. 1121-1127 (1998)
Seya,T.:“CD46(补体膜辅因子蛋白 (MCP)、麻疹病毒受体):物种之间的结构和功能差异(综述)。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Sakata,H.: "A Japanese wild-type measles virus strain inducing predominant early down-rgulation of CD46." Biol.Pharmac.Bull.21. 1121-1127 (1998)
Sakata, H.:“日本野生型麻疹病毒株诱导 CD46 早期显着下调。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SEYA Tsukasa其他文献
SEYA Tsukasa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SEYA Tsukasa', 18)}}的其他基金
An alternative interferon inducing pathway predicted through phylogenetic analyses
通过系统发育分析预测的另一种干扰素诱导途径
- 批准号:
24659214 - 财政年份:2012
- 资助金额:
$ 3.2万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Molecular mechanisms of dendritic cell maturation in response to pattern sensing
树突状细胞成熟响应模式传感的分子机制
- 批准号:
23390120 - 财政年份:2011
- 资助金额:
$ 3.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Pattern-recognition receptors in dendritic cells evoke cellular immunity in response to viral RNA patterns
树突状细胞中的模式识别受体根据病毒 RNA 模式激发细胞免疫
- 批准号:
19209015 - 财政年份:2007
- 资助金额:
$ 3.2万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Molecular mechanism whereby Type I interferon is induced in host immune cells by measles virus infection : possible involvement of Toll-like receptors (TLRs)
麻疹病毒感染在宿主免疫细胞中诱导 I 型干扰素的分子机制:可能涉及 Toll 样受体 (TLR)
- 批准号:
15390154 - 财政年份:2003
- 资助金额:
$ 3.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
相似国自然基金
CD46和DSG2双受体在人B组腺病毒感染与致病中的协同作用和机制研究
- 批准号:32370155
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Novel multipronged Immunovirotherapy Approach for GBM Treatment
GBM 治疗的新型多管齐下免疫病毒治疗方法
- 批准号:
10173067 - 财政年份:2021
- 资助金额:
$ 3.2万 - 项目类别:
Novel multipronged Immunovirotherapy Approach for GBM Treatment
GBM 治疗的新型多管齐下免疫病毒治疗方法
- 批准号:
10557886 - 财政年份:2021
- 资助金额:
$ 3.2万 - 项目类别:
Novel multipronged Immunovirotherapy Approach for GBM Treatment
GBM 治疗的新型多管齐下免疫病毒治疗方法
- 批准号:
10359174 - 财政年份:2021
- 资助金额:
$ 3.2万 - 项目类别:
Neural stem/progenitor cell fate: pathology and protection during CNS infections
神经干/祖细胞命运:中枢神经系统感染期间的病理学和保护
- 批准号:
8812473 - 财政年份:2014
- 资助金额:
$ 3.2万 - 项目类别:
Analysis of neuronal signaling pathways following interferon stimulation
干扰素刺激后的神经信号通路分析
- 批准号:
8255988 - 财政年份:2012
- 资助金额:
$ 3.2万 - 项目类别: